Last reviewed · How we verify
MRG-001
At a glance
| Generic name | MRG-001 |
|---|---|
| Sponsor | MedRegen LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of MRG-001 in Wound Healing in Abdominoplasty Patients (PHASE2)
- MRG-001 as an Immunoregulatory and Regenerative Therapy for ARDS Patients (PHASE2)
- MRG-001 in Patients With Amyotrophic Lateral Sclerosis (PHASE2)
- MRG-001 in Patients With Alcoholic Hepatitis (PHASE2)
- Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL) (PHASE1)
- MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MRG-001 CI brief — competitive landscape report
- MRG-001 updates RSS · CI watch RSS
- MedRegen LLC portfolio CI